WITH THE Multicenter Study of MagLev Technology in Patients Undergoing Mechanical
Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) landmark trial, the fully
levitated magnetic centrifugal pump, HeartMate 3 (HM3; Abbott, Chicago, IL), became
the most widely implanted LVAD device.
1
However, adverse events, such as right ventricular failure, remain high, even with
its improved device design.
2
The lack of a real-world cohort in the MOMENTUM 3 trial remained a critical criticism
of the device's wide acceptance into clinical practice. New trials look to a more
generalizable implant population for matched performance.
3
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiothoracic and Vascular AnesthesiaAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The Society of Thoracic Surgeons Intermacs 2019 annual report: The changing landscape of devices and indications.Ann Thorac Surg. 2020; 109: 649-660
- The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships.J Heart Lung Transplant. 2019; 38: 114-126
- Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: Results from the ELEVATE Registry.Eur Heart J. 2020; 41: 3801-3809
- A fully magnetically levitated left ventricular assist device—Final report.N Engl J Med. 2019; 380: 1618-1627
- Evolving trends in mechanical circulatory support: Clinical development of a fully magnetically levitated durable ventricular assist device.Trends Cardiovasc Med. 2020; 30: 223-229
- Retrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre.Eur J Cardiothorac Surg. 2020; 57: 1160-1165
- Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.J Heart Lung Transplant. 2017; 36: 1080-1086
- Predicting the risk of right ventricular failure in patients undergoing left ventricular assist device implantation: A systematic review.Circ Heart Fail. 2020; 13e006994
- Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes.J Thorac Cardiovasc Surg. 2010; 139: 1316-1324
- Derivation and validation of a novel right-sided heart failure model after implantation of continuous flow left ventricular assist devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) right-sided heart failure risk score.Circulation. 2018; 137: 891-906
Article info
Publication history
Published online: December 14, 2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
